Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
MOVENTIG® (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation
-
IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label
-
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
-
MedImmune receives fast track designation from FDA for development of MEDI3902 for prevention of nosocomial pneumonia
-
Study showed AstraZeneca’s exenatide once-weekly suspension for autoinjection provided superior HbA1c reductions vs. twice-daily exenatide (Byetta®) in adults with type 2 diabetes
-
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
-
AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease
-
AstraZeneca to present research from its innovative diabetes portfolio at the 2014 Meeting of the European Association for the Study of Diabetes
-
Benralizumab Phase II COPD study published in The Lancet Respiratory Medicine
-
AstraZeneca and Redx Pharma agree research collaboration targeting genetic drivers of tumour growth
Latest articles and press releases
All of our latest press releases and articles are available to explore
